GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Kiora Pharmaceuticals
Shares of Kiora, a biopharmaceutical company focused on treating eye diseases, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare retinal diseases. We've categorized it under "Pharma: Eyes." The chart below shows how investors value biotech companies working to save vision.
Broad Market Index - GURU.Markets
Kiora Pharmaceuticals is a biopharmaceutical company developing treatments for rare eye diseases. Its focus on ophthalmology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Kiora compares to the overall market.
Change in the price of a company, segment, and market as a whole per day
KPRX - Daily change in the company's share price Kiora Pharmaceuticals
For Kiora Pharmaceuticals, Inc., which develops drugs for eye diseases, daily volatility reflects sensitivity to clinical trial data. This metric is an important element in assessing risk in this niche.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Kiora Pharmaceuticals specializes in ophthalmology, and its stock volatility is driven by research results and regulatory decisions. The chart below shows average daily fluctuations in this pharmaceutical segment. This serves as a benchmark for assessing how typical KPRX's performance is for its niche.
Daily change in the price of a broad market stock, index - GURU.Markets
Kiora Pharmaceuticals is a biotech company specializing in the treatment of eye diseases. Its stock price depends on clinical trial success and regulatory approvals. These events create unique price movements that contribute to overall volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Kiora Pharmaceuticals
Kiora Pharmaceuticals' year-to-date performance is a story of drug development for rare eye diseases. Its 12-month market cap is entirely dependent on clinical trial data. Success with its lead candidate, which aims to restore vision in patients with retinitis pigmentosa, could be a real breakthrough.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Kiora, as an early-stage biotech, is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about clinical trials of its eye disease drugs. Its stock price will reflect the speculative faith of investors.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kiora Pharmaceuticals, focused on treating eye diseases, is a biotech company whose value is closely tied to research progress. Comparing its year-over-year market capitalization dynamics with the broader market allows us to see how clinical trial successes, or conversely, failures, can trigger sharp stock price movements independent of overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Kiora Pharmaceuticals
Kiora Pharmaceuticals is a biopharmaceutical company focused on eye diseases. Its monthly performance is entirely dependent on progress in its clinical programs. News of trial results for its drugs for rare retinal diseases is the main driver of its value.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Kiora Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare eye diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, it is possible to assess the progress of its pipeline of candidates for the treatment of conditions such as retinitis pigmentosa in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Kiora Pharmaceuticals is a biopharmaceutical company focused on treating eye diseases. Its shares are buoyed by anticipation of clinical trial results. The chart shows that the company's monthly share price fluctuations are unrelated to overall market trends, but rather reflect specific scientific news.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. Its weekly stock price is volatile and depends on the results of clinical trials.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
Kiora Pharmaceuticals focuses on treating eye diseases. The chart compares the weekly stock performance of this highly specialized company with the broader pharmaceutical sector. Does its niche allow it to chart a trajectory independent of global industry trends?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Kiora Pharmaceuticals is another biotech company whose shares exist in their own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
KPRX - Market capitalization of the company Kiora Pharmaceuticals
Kiora Pharmaceuticals is a company focused on developing drugs for rare eye diseases. Its market cap reflects investors' confidence in its clinical-stage pipeline. It's a highly volatile curve driven by research and funding news.
KPRX - Share of the company's market capitalization Kiora Pharmaceuticals within the market segment - Pharma eyes
Kiora Pharmaceuticals is a biopharmaceutical company specializing in developing treatments for rare eye diseases. In this segment, its market capitalization reflects the potential of its drug candidates. The dynamics of this metric are a sensitive barometer of clinical trial news, which determines the company's future.
Market capitalization of the market segment - Pharma eyes
Kiora Pharmaceuticals is saving sight by developing drugs to treat rare eye diseases. How big is this arena? The chart below shows the overall market capitalization of the ophthalmology pharmaceutical sector. Its dynamics reflect the enormous investment and hopes associated with finding cures for diseases that lead to blindness.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Kiora Pharmaceuticals chart shows how the market values the development of drugs for rare eye diseases. Its market cap represents a venture capital bet on the success of its products in clinical trials. This diagram illustrates how a focus on ophthalmology can create value if successful.
Book value capitalization of the company, segment and market as a whole
KPRX - Book value capitalization of the company Kiora Pharmaceuticals
The book value of Kiora Pharmaceuticals, a company specializing in eye diseases, is its tangible capital base, consisting of the rights to its pipeline of drug candidates and the financial reserves for their clinical development. The chart below shows how this scientific and financial capital has changed.
KPRX - Share of the company's book capitalization Kiora Pharmaceuticals within the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company. Its tangible assets are research laboratories where drugs for rare eye diseases are developed. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - Pharma eyes
Kiora Pharmaceuticals is a biopharmaceutical company. Pharmaceuticals, as the chart shows, are knowledge- and capital-intensive. Kiora focuses on drug development, and its capital is its intellectual property and R&D infrastructure.
Book value of all companies included in the broad market index - GURU.Markets
Kiora's assets are not its manufacturing plants, but rather a pipeline of drug developments for rare eye diseases. Its book value reflects the capital the company invests in clinical trials of its candidates aimed at preserving and restoring vision.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Kiora Pharmaceuticals
Kiora Pharmaceuticals develops drugs to treat rare eye diseases. Its market capitalization is a bet on its pipeline. The chart shows the risks and hopes associated with finding drugs to restore vision.
Market to book capitalization ratio in a market segment - Pharma eyes
Kiora Pharmaceuticals is a biotech company focused on treating rare eye diseases. Its value depends on the success of its clinical programs. The chart shows how investors value its ophthalmology pipeline.
Market to book capitalization ratio for the market as a whole
Kiora Pharmaceuticals specializes in treating eye diseases. Its patent portfolio and clinical trial data are its core assets. This chart illustrates how market valuations in ophthalmology reflect the potential for vision restoration and the market size for new therapies.
Debts of the company, segment and market as a whole
KPRX - Company debts Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. Pharmaceutical development, especially for niche markets, requires significant investment. This chart shows how the company raises capital to fund its clinical trials and advance its candidates toward potential approval.
Market segment debts - Pharma eyes
Kiora Pharmaceuticals is a clinical-stage ophthalmology company. Developing drugs to treat eye diseases is a long and expensive process. This chart shows its financial position and ability to fund its clinical programs until results are achieved.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage ophthalmology company. This chart shows its financial structure. Its debt burden increases the risk if clinical trials fail to yield expected results, which could jeopardize the company's future.
Market segment debt to market segment book capitalization - Pharma eyes
Kiora Pharmaceuticals is a biopharmaceutical company focused on treating rare eye diseases. Developing ophthalmic drugs is a complex and expensive process. The chart shows the overall debt burden in the pharmaceutical industry, providing context for assessing Kiora's financial strategy on its path to commercialization.
Debt to book value of all companies in the market
Kiora Pharmaceuticals is a clinical-stage ophthalmology company. Developing eye drugs is a long and expensive process. This chart clearly shows that for companies whose value lies in their intellectual property, the debt market is closed. Financing is only possible through equity funding from investors who believe in their science.
P/E of the company, segment and market as a whole
P/E - Kiora Pharmaceuticals
For Kiora Pharmaceuticals, a company developing drugs to treat eye diseases, the P/E ratio is not applicable. The company has no profit. Its valuation is a bet on its scientific developments and the success of its products in clinical trials, which is a high-risk proposition.
P/E of the market segment - Pharma eyes
Kiora Pharmaceuticals is a clinical-stage ophthalmology company developing drugs to treat rare eye diseases such as retinitis pigmentosa. This chart shows the average valuation for the sector, providing investors with context for evaluating Kiora's research portfolio.
P/E of the market as a whole
Kiora Pharmaceuticals is a biopharmaceutical company specializing in the treatment of eye diseases. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Kiora Pharmaceuticals
Kiora Pharmaceuticals is a biopharmaceutical company developing drugs to treat rare eye diseases. This chart reflects investor expectations for the clinical trials of its candidates. The assessment is based on the potential to offer treatment to patients with untreated ophthalmological conditions, such as retinitis pigmentosa.
%20P%2FE%20Kiora%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Kiora-Pharmaceuticals&v=1772624353014 "Chart of the company's future (projected) P/E Kiora Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. Its valuation relative to other biotechs in the field reflects investor sentiment about its clinical pipeline. This reflects how the market assesses the success rate of its candidates and their potential to address patient needs.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772624353043 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Kiora Pharmaceuticals is a clinical-stage biopharmaceutical company focused on treating rare eye diseases. Its future depends on the results of clinical trials. This chart shows the overall risk tolerance of investors. For biotech companies working with orphan diseases, a positive market environment makes it easier to raise capital to complete development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772624353122 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage ophthalmology company developing drugs for the treatment of rare eye diseases. The financial indicators reflected here represent investments in clinical research. Success depends on trial results and the potential for vision restoration in patients.
Profit of companies in the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. This chart shows the overall profitability of the ophthalmology pharmaceutical sector. It helps understand how successful a strategy of focusing on orphan diseases can be in this narrow but important area of medicine.
Overall market profit
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. Its future depends on the results of clinical trials. The macroeconomic situation, reflected in this chart, affects it solely through the availability of capital for R&D.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat eye diseases. Its future profit forecast depends on the success of its clinical trials. This chart shows how analysts assess the potential of its developments to address vision problems.
%20profit%20of%20the%20company%20Kiora%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Kiora-Pharmaceuticals&v=1772624353254 "Graph of future (projected) profit of the company Kiora Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma eyes
Kiora Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare eye diseases. Their developments are aimed at restoring vision in patients with degenerative retinal diseases. This chart shows the outlook for ophthalmic pharmaceuticals. It illustrates the high risk and enormous potential of technologies that can restore vision.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772624353282 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
For Kiora Pharmaceuticals, a company focused on treating ophthalmological diseases, this schedule is important for the investment climate. Optimistic economic forecasts facilitate raising the capital needed to conduct expensive clinical trials and bring drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772624353331 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. This metric reflects investors' assessment of its clinical pipeline and potential future revenue.
P/S market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. This chart shows the average valuation in the pharmaceutical sector. It reflects investor expectations for Kiora's potential to address vision problems for which there is currently no effective treatment.
P/S of the market as a whole
Kiora Pharmaceuticals, Inc. is a clinical-stage ophthalmology company developing drugs for rare eye diseases. The company's valuation is based on the combined potential of its pipeline. This chart helps assess the risks and potential rewards in the highly specialized field of ophthalmology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. Its valuation is based on the future potential of its portfolio. The chart reflects investors' confidence that its candidates will successfully complete clinical trials and help patients with vision loss.
%20P%2FS%20Kiora%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Kiora-Pharmaceuticals&v=1772624353535 "The graph of the company's future (projected) P/S Kiora Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare retinal diseases such as retinitis pigmentosa. Its goal is to preserve and restore vision in patients. This chart shows how investors view the potential of its niche developments compared to other pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772624353572 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the pharmaceutical market. For Kiora Pharmaceuticals, a company developing drugs to treat rare eye diseases, it's an indicator of the investment climate. Market optimism allows it to attract funding for research that could restore or preserve vision for patients with limited treatment options.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772624353687 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing treatments for rare eye diseases such as retinitis pigmentosa. This chart reflects revenue from partnerships. Future revenue will depend on the success of clinical trials and the commercialization of its vision-restoring and vision-preserving drugs.
Sales of companies in the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. This chart shows the dynamics of the ophthalmic pharmaceutical sector. Kiora is working on developing therapies for conditions such as retinitis pigmentosa, offering hope to patients at risk of vision loss.
Overall market sales
Kiora Pharmaceuticals is a biopharmaceutical company specializing in eye treatments. Its success depends on clinical trial results and regulatory approval. The overall economic situation, shown in this chart, impacts the availability of capital for R&D and the healthcare system's ability to finance innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. Its future depends on the success of clinical trials. This chart reflects analysts' assessment of the scientific and commercial potential of the company's vision preservation and restoration pipeline.
%20sales%20of%20the%20company%20Kiora%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Kiora-Pharmaceuticals&v=1772624353937 "Schedule of future (projected) sales of the company Kiora Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. This chart shows expectations for the pharmaceutical sector focused on ophthalmology. It reflects the need for innovative treatments to preserve patients' vision.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772624353960 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Kiora Pharmaceuticals, Inc. is a clinical-stage ophthalmology company developing drugs for rare eye diseases. Its valuation is dependent on the results of clinical trials. This schedule, reflecting the state of the economy, affects the availability of capital for biotech companies working on drugs for orphan (rare) diseases, which require significant investment.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772624353979 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Kiora Pharmaceuticals
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. This chart shows the company's financial performance during the clinical trials phase. Negative values represent investments in saving vision, which, if successful, could generate significant profits and benefits for patients.
Market segment marginality - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. For a clinical-stage company, this chart is important as an indicator of potential. It reflects the average profitability in its sector, which Kiora aims to achieve if it successfully brings its specialized drugs to market.
Market marginality as a whole
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. This overall market profitability chart is not a defining indicator for the company. Its future success depends on the results of clinical trials and the ability to offer new treatments to patients with currently limited options.
Employees in the company, segment and market as a whole
Number of employees in the company Kiora Pharmaceuticals
Kiora Pharmaceuticals is a pharmaceutical company focused on developing treatments for rare eye diseases. This graph shows a small team managing clinical trials. Their size is typical for a company whose core value is intellectual property.
Share of the company's employees Kiora Pharmaceuticals within the market segment - Pharma eyes
Kiora Pharmaceuticals is focused on treating rare eye diseases. In this narrow and complex field of ophthalmology, its team of scientists is its greatest asset. This metric reflects the percentage of leading ophthalmologists and biologists working on new treatments the company attracts, demonstrating its unique concentration of scientific expertise.
Number of employees in the market segment - Pharma eyes
Kiora Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare eye diseases. Preserving vision is one of the most important goals in medicine. This graph shows that new treatments are constantly emerging in ophthalmology, requiring deep scientific expertise from scientists and bringing hope to millions of patients.
Number of employees in the market as a whole
Kiora Pharmaceuticals focuses on treating ophthalmological diseases, serving an important medical niche. This chart shows the overall employment landscape, which is comprised of numerous such specialized segments. Success in each contributes to the overall health of the nation and the economy by creating jobs for highly specialized professionals.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Kiora Pharmaceuticals (KPRX)
Kiora Pharmaceuticals is a biotech company specializing in eye diseases. This chart represents a pure intellectual capital valuation. The company's value is based on market expectations for its drug candidates in this complex field. The chart shows the high future value the market attributes to these developments, per scientist.
%20of%20the%20company%20Kiora%20Pharmaceuticals%20(KPRX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Kiora-Pharmaceuticals-KPRX&v=1772624354348 "Chart of market capitalization per employee (in thousands of dollars) of the company Kiora Pharmaceuticals (KPRX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Kiora Pharmaceuticals specializes in drugs for rare eye diseases. This is a highly specialized area of pharmaceuticals. The chart shows how the market values their niche expertise and development portfolio. This indicates the value of their focused strategy.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772624354398 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Kiora Pharmaceuticals is a biopharmaceutical company specializing in the treatment of eye diseases. This chart shows the average market value generated by one specialist, highlighting the importance of ophthalmology research.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772624354521 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Kiora Pharmaceuticals (KPRX)
Kiora Pharmaceuticals is a clinical-stage biotech company focused on eye diseases. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company "burns" per scientist.
%20Chart%20Kiora%20Pharmaceuticals%20(KPRX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Kiora-Pharmaceuticals-KPRX&v=1772624354635 "Company Profit Per Employee (in thousands of dollars) Chart Kiora Pharmaceuticals (KPRX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases. Its business is focused on clinical research. The negative earnings per employee, which this chart likely shows, is standard for the biotech industry and reflects significant investment in the research team in anticipation of product approval and launch.
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772624354658 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Kiora Pharmaceuticals (KPRX) is a clinical-stage biotech focused on developing drugs for *rare eye diseases*. It's an R&D company. This chart shows the market average dollar return per employee. For KPRX (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average if successful.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772624354697 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Kiora Pharmaceuticals (KPRX)
Kiora Pharmaceuticals is a biopharmaceutical company focused on treating rare eye diseases. This graph shows the path from research to market. For a company in development, it reflects the future potential when successful commercialization of the drug could generate significant revenue.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Kiora-Pharmaceuticals-KPRX&v=1772624354843 "Sales chart per company employee Kiora Pharmaceuticals (KPRX)")
Sales per employee in the market segment - Pharma eyes
Kiora Pharmaceuticals is a clinical-stage biotech company focused on treating rare eye diseases. Revenue is not yet available. This chart shows the average revenue per employee in the segment, a benchmark for commercial pharmaceutical companies. It provides context for assessing the effectiveness of Kiora's staff.
Sales per employee for the market as a whole
Kiora Pharmaceuticals is a clinical-stage biotech company focused on treating rare eye diseases. The company has no commercial products or revenue, which is irrelevant. Their entire value lies in the potential of their R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company Kiora Pharmaceuticals (KPRX)
Kiora Pharmaceuticals is a biotech company focused on treating rare eye diseases. The company has a history of failures. This chart shows the odds that their current developments will suffer the same fate. "Bears" believe their drug candidates will fail to prove effective in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Kiora-Pharmaceuticals-KPRX&v=1772624354970 "Short Shares Chart for the Company Kiora Pharmaceuticals (KPRX)")
Shares shorted by market segment - Pharma eyes
Kiora Pharmaceuticals (KPRX) is a biopharmaceutical company focused on treating rare eye diseases such as retinitis pigmentosa. This chart shows the total short position in the ophthalmology biotech sector. The high figure indicates general investor skepticism about the success of clinical trials in this complex niche.
Shares shorted by the overall market
Kiora (KPRX) is a clinical-stage biotech. Its value reflects the hope for future success. When this indicator of overall pessimism rises, investors are less inclined to hope. They are dumping unprofitable companies en masse, requiring refinancing.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Kiora Pharmaceuticals (KPRX)
Kiora Pharmaceuticals (KPRX) focuses on developing treatments for rare eye diseases. Vision loss is a serious issue, and breakthroughs are highly valued. This chart measures the rate of price change. It shows when the stock is "overheated" (above 70) due to anticipation of trial data or "oversold" (below 30) due to a lack of progress, indicating a potential reversal.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Kiora-Pharmaceuticals-KPRX&v=1772624355084 "RSI 14 indicator chart for the company's stock Kiora Pharmaceuticals (KPRX)")
RSI 14 Market Segment - Pharma eyes
Kiora Pharmaceuticals is a biopharmaceutical company specializing in ophthalmology. It develops drugs to treat rare eye diseases, such as retinitis pigmentosa. This chart shows the overall sentiment in the ophthalmic pharmaceutical sector. It helps us understand whether KPRX's performance is a reaction to its clinical data or part of a broader trend in this niche.
RSI 14 for the overall market
Kiora Pharmaceuticals (KPRX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast KPRX (Kiora Pharmaceuticals)
Kiora Pharmaceuticals is a biotech company focused on treating rare eye diseases (retinitis). This chart shows the average target price. Analysts' estimates are based on clinical data for its lead candidate (KIO-301) and its potential for vision restoration.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-KPRX-Kiora-Pharmaceuticals&v=1772624355200 "A chart showing analyst consensus forecasts for the expected stock price. KPRX (Kiora Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price KPRX (Kiora Pharmaceuticals)
Kiora Pharmaceuticals is a biotech company focused on developing drugs for rare eye diseases. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in their R&D portfolio and the chances of success in complex ophthalmology research.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-KPRX-Kiora-Pharmaceuticals&v=1772624355214 "A chart showing the difference between the consensus forecast and the actual stock price. KPRX (Kiora Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Kiora Pharmaceuticals is an ophthalmology company developing drugs to treat rare eye diseases such as retinitis pigmentosa. This chart shows analysts' overall expectations for the ophthalmic pharmaceutical sector. It reflects whether experts believe breakthroughs in the treatment of rare retinal diseases are possible.
Analysts' consensus forecast for the overall market share price
Kiora Pharmaceuticals (KPRX) is a clinical-stage biopharmaceutical company focused on treating rare eye diseases (retinitis pigmentosa). This is a high-risk scientific endeavor. This chart shows the overall risk appetite in the market and serves as an indicator of the "open" or "closed" funding window for speculative biotechs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Kiora Pharmaceuticals
Kiora Pharmaceuticals is a lifesaver for the eyes. It's a biotech company whose signature feature is an R&D platform for treating rare retinal diseases (retinitis pigmentosa). This chart is a pure indicator of their R&D. Its dynamics depend entirely on their (very risky) clinical trial data and their chances of a breakthrough in this complex field.
AKIMA Market Segment Index - Pharma eyes
Kiora Pharmaceuticals (KPRX) is a biopharmaceutical company specializing in ophthalmology. They develop drugs to treat rare and severe eye diseases, such as retinitis pigmentosa. This chart shows the average index for the segment. It helps investors assess how Kiora's risks in this niche compare to the industry average.
The AKIM Index for the overall market
Kiora Pharmaceuticals is a company developing treatments for rare ophthalmological diseases (retinitis pigmentosa). This chart, which reflects the market average, provides a macro backdrop. It helps assess how KPRX, a niche scientific company, compares to overall economic trends.
